Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood enzyme may reveal hidden clues in schizoaffective disorder

NCT ID NCT07673718

Knowledge-focused Sponsor: Elazığ Mental Health and Diseases Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study examines whether levels of a blood enzyme called α-N-acetylgalactosaminidase differ between people with schizoaffective disorder during acute episodes and those in remission, compared to healthy individuals. The goal is to better understand the biological processes behind the condition and explore if this enzyme could serve as a marker of disease activity. Researchers will also look at how enzyme levels relate to symptom severity and inflammation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If α-N-acetylgalactosaminidase levels correlate with disease state, it could become a blood test to help track schizoaffective disorder activity.
What could go wrong
This is a small, early observational study, not a treatment trial. The enzyme may not reliably distinguish between phases or predict outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

93 people

The number who actually took part.

Started

Apr 2025

Finished

Jul 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of adult participants aged 18-65 years. The schizoaffective disorder (SAD) group will include consecutive subjects diagnosed with SAD according to DSM-5-TR criteria who will be admitted to the psychiatry clinic of Elazığ Mental Health and Diseases Hospital (Turkey). The healthy control (HC) group will consist of individuals from the general population who will apply to the hospital medical board and will have no current or past psychiatric or significant medical disorders. All participants will provide informed consent prior to enrollment.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

1. For Schizoaffective Disorder (SAD) Group: \*Inclusion Criteria: * Diagnosis of SAD according to DSM-5-TR * Acute exacerbation episode or remission phase * Medication-free for at least one month prior to admission for acute exacerbation episode and regular medication use for remission use * Age ≥ 18 years and \<65 years * Provided informed consent For Schizoaffective Disorder (SAD) Group: \*Exclusion Criteria: • Hypertension • Diabetes mellitus • Chronic kidney disease • Rheumatoid arthritis • Systemic lupus erythematosus • Cardiac illness • Severe neurological disorders • Immunological or systemic illness • Primary psychiatric disorders other than SAD * Alcohol/drug/substance use 2. For Healthy Control Group: \*Inclusion Criteria: • No psychiatric diagnosis • No systemic or immunological illness * Medication-free for at least one month * Age ≥ 18 years and \< 65 years * Provided informed consent For Healthy Control Group: \*Exclusion Criteria: * Hypertension * Diabetes mellitus * Chronic kidney disease * Rheumatoid arthritis * Systemic lupus erythematosus * Cardiac illness * Severe neurological disorders * Immunological or systemic illness * Having psychiatric disorders * Alcohol/drug/substance use

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Schizoaffective disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Psychotic Disorders schizoaffective disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Schizoaffective disorder

Contacts and locations

Locations

  • Elazığ Mental Health and Diseases Hospital Psychiatry Clinic

    Elâzığ, Elâzığ, 23200, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.